Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.
圣地亚哥，2024年11月25日（全球新闻网络）—— kura oncology, Inc.（纳斯达克：KURA）是一家临床阶段的生物制药公司，致力于实现精准医学在癌症治疗中的承诺，今天宣布参与即将举行的 JMP Securities 血液学和肿瘤学峰会。Troy Wilson, Ph.D., J.D.，总裁兼首席执行官，定于2024年12月2日下午2:00（东部时间）/上午11:00（太平洋时间）参加一次虚拟炉边聊天。
A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at , with an archived replay available following the live event.
炉边聊天的现场音频网络广播将在 Kura 的网站投资者部分提供，直播活动结束后会有档案重播。
About Kura Oncology
关于kura oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.
Kura Oncology是一家临床阶段的生物制药公司，致力于实现精准医学在癌症治疗中的承诺。公司的管道包括针对癌症信号通路的小分子药物候选者。Ziftomenib是一种每日一次口服的menin抑制剂，是首个也是唯一一个获得美国食品和药物管理局（FDA）突破性治疗认定的研究疗法，旨在治疗复发/难治性（R/R）NPM1突变急性髓性白血病（AML）。2024年11月，Kura与共立株式会社达成了一项全球战略合作协议，以开发和商业化ziftomenib用于急性髓性白血病和其他血液恶性肿瘤。在复发/难治性NPM1突变急性髓性白血病的ziftomenib II期注册指导试验中已完成入组，双方预计将在2025年提交新药申请。Kura还在进行一系列临床试验，以评估ziftomenib与新诊断和复发/难治性NPM1突变和KMT2A重排急性髓性白血病的标准治疗的联合应用。KO-2806，一种下一代法尼酰转移酶抑制剂，正在进行I期剂量递增试验，作为单药疗法和与靶向治疗的组合。Tipifarnib，一种强效且选择性FTI，目前正在与alpelisib联合进行I/II期试验，适用于PIK3CA依赖的头颈部鳞状细胞癌。有关更多信息，请访问Kura的网站，并在X和LinkedIn上关注我们。
Kura Contacts
kura oncology 联系人
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
投资者:
Pete De Spain
执行副总裁，投资者关系
企业通讯
858-500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
媒体:
Cassidy McClain
副总裁
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
